Geode Capital Management LLC Sells 8,363 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

Geode Capital Management LLC cut its position in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 0.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,406,876 shares of the biopharmaceutical company’s stock after selling 8,363 shares during the period. Geode Capital Management LLC owned about 2.24% of MacroGenics worth $4,629,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its stake in MacroGenics by 39.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 661,914 shares of the biopharmaceutical company’s stock worth $2,178,000 after purchasing an additional 186,858 shares during the period. Frazier Life Sciences Management L.P. raised its stake in MacroGenics by 21.8% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,010,727 shares of the biopharmaceutical company’s stock worth $12,796,000 after acquiring an additional 539,023 shares in the last quarter. Millennium Management LLC boosted its position in MacroGenics by 3,473.7% in the second quarter. Millennium Management LLC now owns 3,312,672 shares of the biopharmaceutical company’s stock valued at $14,079,000 after buying an additional 3,219,977 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of MacroGenics by 35.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 566,328 shares of the biopharmaceutical company’s stock worth $1,863,000 after acquiring an additional 147,438 shares in the last quarter. Finally, FMR LLC grew its position in MacroGenics by 1,230.1% during the 3rd quarter. FMR LLC now owns 137,215 shares of the biopharmaceutical company’s stock worth $451,000 after acquiring an additional 126,899 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MGNX has been the subject of several research analyst reports. JMP Securities downgraded MacroGenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. Evercore ISI raised MacroGenics to a “strong-buy” rating in a research note on Monday, September 16th. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price objective on shares of MacroGenics in a research report on Wednesday, November 6th. Finally, StockNews.com raised MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. Eight investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.63.

MacroGenics Stock Up 4.8 %

Shares of NASDAQ MGNX opened at $3.46 on Monday. MacroGenics, Inc. has a twelve month low of $2.95 and a twelve month high of $21.88. The stock has a market cap of $217.16 million, a price-to-earnings ratio of -2.19 and a beta of 2.04. The company’s fifty day moving average is $3.51 and its 200-day moving average is $3.76.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.